叶轮
医学
心源性休克
经皮冠状动脉介入治疗
传统PCI
心脏病学
心肌梗塞
内科学
心力衰竭
射血分数
血流动力学
经皮
心室辅助装置
外科
作者
Rafiq Bhat,Syed Manzoor Ali,Akanksha Rathi,Javaid Akhter Bhat,Raja Saqib Iqbal,Monowarul Islam,Syed Maqbool,Abhishek Tibrewal,Yongsheng Qu,You Zhang,Yuxiao Sun,Wei Xiao,Chuanyu Gao
出处
期刊:Perfusion
[SAGE]
日期:2021-09-28
卷期号:38 (1): 208-213
标识
DOI:10.1177/02676591211049018
摘要
Acute myocardial infarction (AMI) complicated by cardiogenic shock (AMI-CS) or heart failure is associated with an unacceptably high in-hospital mortality of 33%-55% and a lost chance to accept PCI (Percutaneous Coronary Intervention).The aim of the study was to find out whether percutaneous hemodynamic support device Impella 2.5 improves prognosis of high-risk PCI patients or not.This study was a case series involving six patients who underwent a Left Ventricular Assist Device (LVAD, Impella 2.5, Abiomed, Danvers, MA) implantation after suffering from AMI with a very low ejection fraction and acute heart failure. The clinical experience and outcomes of the patients are hereby discussed.All PCI procedures were safely completed under LVAD support. The hemodynamic parameters of all patients improved clinically over the next 30 days and following 12 months after Impella insertion except in two patients, of which one patient (Case number 6) died 4 days post-Impella protected PCI procedure due to acute left ventricle heart failure with cardiogenic shock and pulmonary oedema; and another one died at 12 months after Impella protected PCI procedure (Case number 4) due to decompensated heart failure and infected pneumonia.Percutaneous hemodynamic support is favorable and feasible during high risk Percutaneous Coronary Intervention (PCI). A bigger study is needed to substantiate the claims of the current study.
科研通智能强力驱动
Strongly Powered by AbleSci AI